SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMcbride Regulatory News (MCB)

Share Price Information for Mcbride (MCB)

Share Price is delayed by 15 minutes
Get Live Data
141.60    -24.20 (-14.60%)
Bid:
140.20
Ask:
144.80
Spread: 4.60 (3.281%)
Market Cap: £241.94m
MCB Live PriceLast checked at - London Stock Exchange

Intraday Mcbride Share Chart

Trading Update

10 Jan 2019 07:00

RNS Number : 6695M
McBride PLC
10 January 2019
 

10 January 2019

 

McBride plc

 

Trading Update

 

McBride plc (the "Group"), the leading European manufacturer and supplier of Contract Manufactured and Private Label products for the domestic Household and professional cleaning and hygiene markets, today provides a trading update for the six months ended 31 December 2018.

 

The Group's first half continuing revenues at constant currency were 10.8% higher than the prior year. Excluding the benefit of first quarter revenues from Danlind, continuing underlying revenues were 6.0% higher. Underlying Household division sales were 5.9% higher, primarily as a result of higher sales in the East and UK regions (up 23.4% and 10.5% respectively).

 

As outlined in our recent AGM trading update, the first half year has seen raw material, packaging and logistics costs higher than anticipated, particularly in the second quarter. These have been partly mitigated by improved sales volumes and lower overheads. The pricing outlook for many of our key raw materials has improved recently and in the absence of this reversing significantly, the Board expects full year earnings to be in line with expectations, with full year profit delivery weighted to the second half.

The sale of the European Personal Care Liquids business was successfully completed during the second quarter and we continue to progress plans for the closure of our UK Aerosols factory in the second half year as expected. The integration of Danlind continued with our Danish factories transitioning onto the McBride ERP system in December.

 

The Group will announce its interim results for the six months ended 31 December 2018 on 21 February.

 

Rik De Vos, Chief Executive said;

 

"The Group has made significant strategic progress in the first half of this financial year completing the sale of Personal Care Liquids, integrating Danlind onto the McBride systems and managing our revenue growth. Margins remain our key focus at present and the recent improvement in the pricing outlook for raw materials following almost two years of significant inflation will see some recovery of the cumulative cost impact to the business. I remain confident that the Group continues to be well positioned to exploit the growth and margin opportunities in the remainder of this financial year and beyond."

 

 

For further information please contact:

 

McBride plc

Rik De Vos, Chief Executive Officer

0161 203 7570

Chris Smith, Chief Financial Officer

0161 203 7570

FTI Consulting

020 3727 1017

Ed Bridges, Nick Hasell

 

Note: This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation which came into effect on 3 July 2016.

 

-Ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTQKLFBKFFLBBV
Date   Source Headline
1st Mar 20214:51 pmRNSTransaction in Own Shares
26th Feb 20215:03 pmRNSTransaction in Own Shares
25th Feb 20215:38 pmRNSDirector/PDMR Shareholding
25th Feb 20214:57 pmRNSTransaction in Own Shares
24th Feb 20214:56 pmRNSTransaction in Own Shares
23rd Feb 20214:53 pmRNSTransaction in Own Shares
23rd Feb 20217:01 amRNSCapital Markets Day
23rd Feb 20217:00 amRNSHalf-year Report
22nd Feb 20214:56 pmRNSTransaction in Own Shares
19th Feb 20214:59 pmRNSTransaction in Own Shares
18th Feb 20214:59 pmRNSTransaction in Own Shares
17th Feb 20214:54 pmRNSTransaction in Own Shares
16th Feb 20214:57 pmRNSTransaction in Own Shares
15th Feb 20214:52 pmRNSTransaction in Own Shares
12th Feb 20214:58 pmRNSTransaction in Own Shares
11th Feb 20214:50 pmRNSTransaction in Own Shares
10th Feb 20215:00 pmRNSTransaction in Own Shares
10th Feb 20217:00 amRNSNotice of Results and Capital Markets Day
9th Feb 20215:05 pmRNSTransaction in Own Shares
9th Feb 20218:53 amRNSAppointment of Joint Broker
8th Feb 20214:58 pmRNSTransaction in Own Shares
5th Feb 20214:56 pmRNSTransaction in Own Shares
4th Feb 20215:06 pmRNSTransaction in Own Shares
3rd Feb 20214:58 pmRNSTransaction in Own Shares
2nd Feb 20215:01 pmRNSTransaction in Own Shares
1st Feb 20215:01 pmRNSTransaction in Own Shares
29th Jan 20214:55 pmRNSTransaction in Own Shares
28th Jan 20214:56 pmRNSTransaction in Own Shares
27th Jan 20215:02 pmRNSTransaction in Own Shares
26th Jan 20215:03 pmRNSTransaction in Own Shares
25th Jan 20215:15 pmRNSTransaction in Own Shares
25th Jan 20219:06 amRNSTransaction in Own Shares
25th Jan 20219:05 amRNSTransaction in Own Shares
20th Jan 20215:17 pmRNSTransaction in Own Shares
19th Jan 20215:26 pmRNSTransaction in Own Shares
15th Jan 20214:59 pmRNSTransaction in Own Shares
14th Jan 20214:54 pmRNSTransaction in Own Shares
13th Jan 20215:00 pmRNSTransaction in Own Shares
12th Jan 20214:54 pmRNSTransaction in Own Shares
11th Jan 20214:58 pmRNSTransaction in Own Shares
8th Jan 20214:57 pmRNSTransaction in Own Shares
8th Jan 202111:32 amRNSDirector/PDMR Shareholding
8th Jan 202110:43 amRNSTransaction in Own Shares
7th Jan 20215:02 pmRNSTransaction in Own Shares
7th Jan 20214:52 pmRNSTransaction in Own Shares
7th Jan 20218:46 amRNSHolding(s) in Company
6th Jan 20215:16 pmRNSTransaction in Own Shares
6th Jan 20214:26 pmRNSHolding(s) in Company
5th Jan 20214:58 pmRNSTransaction in Own Shares
29th Dec 20205:19 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.